Sight Sciences Files 8-K on Financial Obligation & Equity Sales

TL;DR

Sight Sciences took on new debt and sold unregistered equity on Dec 11.

AI Summary

On December 11, 2024, Sight Sciences, Inc. filed an 8-K report detailing two key events. The company entered into a direct financial obligation under a credit agreement, the specifics of which are not detailed in this filing. Additionally, Sight Sciences reported unregistered sales of equity securities, also without specific details provided in this document.

Why It Matters

This filing indicates potential new debt or financing arrangements and equity transactions for Sight Sciences, which could impact its financial structure and shareholder dilution.

Risk Assessment

Risk Level: medium — The filing mentions a new financial obligation and unregistered equity sales, which can introduce financial risk and potential dilution for existing shareholders.

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant
• December 11, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT Nasdaq Glo
• $5.0 million — mpany") consummated the drawdown of the $5.0 million Tranche 1(b) Term Loan Advance (the "Tr
• $65.0 million — gate original principal amount of up to $65.0 million (the "Term Loan Facility"). Upon consum
• $40.0 million — of borrowings under theLoan Agreementwas$40.0 million. The Term Loan Facility has a maturit
• $0.1 m — rincipal amount of the Tranche Loan, or $0.1 million, divided by the volume-weighted a

Filing Documents

• sght-20241211.htm (8-K) — 50KB
• 0000950170-24-135402.txt ( ) — 176KB
• sght-20241211.xsd (EX-101.SCH) — 32KB
• sght-20241211_htm.xml (XML) — 5KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities On the Closing Date, as contemplated by the Loan Agreement, the Company issued warrants to the Lenders to purchase that aggregate number of shares of the Company's common stock, par value $0.001 per share ("common stock"), equal to two percent (2.0%) of the principal amount of the Tranche Loan, or $0.1 million, divided by the volume-weighted average price of the common stock for the five-day period preceding the Closing Date. Each warrant is exercisable for seven years from its date of issuance and tradeable in accordance with the provisions of Rule 144 of the Securities Act of 1933, as amended.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: December 11, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR